Biosphere Clinical Research Profile
Key Indicators
- Authorised Capital ₹ 0.10 M
as on 08-12-2024
- Paid Up Capital ₹ 0.10 M
as on 08-12-2024
- Company Age 12 Year, 2 Months
- Last Filing with ROC 31 Mar 2024
- Open Charges ₹ 4.44 M
as on 08-12-2024
- Revenue 61.06%
(FY 2022)
- Profit 397.33%
(FY 2022)
- Ebitda 381.91%
(FY 2022)
- Net Worth 41.73%
(FY 2022)
- Total Assets 21.59%
(FY 2022)
About Biosphere Clinical Research
The Company is engaged in the Travel And Hospitality Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2024. It's a company limited by shares with an authorized capital of Rs 0.10 M and a paid-up capital of Rs 0.10 M.
The company currently has active open charges totaling ₹4.44 M.
Neeta Nargundkar and Uday Nargundkar serve as directors at the Company.
- CIN/LLPIN
U24233MH2012PTC236944
- Company No.
236944
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
17 Oct 2012
- Date of AGM
30 Sep 2024
- Date of Balance Sheet
31 Mar 2024
- Listing Status
Unlisted
- ROC Code
Roc Mumbai
Industry
Company Details
- Location
Thane, Maharashtra, India
- Telephone
- Email Address
- Website
- Social Media
Who are the key members and board of directors at Biosphere Clinical Research?
Executive Team (1)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Neeta Nargundkar  | Managing Director | 17-Oct-2012 | Current |
Board Members(1)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
| Uday Nargundkar | Director | 24-Feb-2018 | Current |
Financial Performance of Biosphere Clinical Research.
Biosphere Clinical Research Private Limited, for the financial year ended 2022, experienced significant growth in revenue, with a 61.06% increase. The company also saw a substantial improvement in profitability, with a 397.33% increase in profit. The company's net worth Soared by an impressive increase of 41.73%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metric |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
| ||||||
| Revenue from Operations |
| ||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Biosphere Clinical Research?
In 2021, Biosphere Clinical Research had a promoter holding of 100.00%. The company had 1 Associate company. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Related Corporates (Common Directorship)
Sprutha Impex Private LimitedActive 6 years 3 monthsNeeta Nargundkar and Uday Nargundkar are mutual person
Charges (Loans)
| Lender | Amount | Status |
|---|---|---|
Tjsb Sahakari Bank Limited Creation Date: 07 Oct 2024 | ₹3.00 M | Open |
Hdfc Bank Limited Creation Date: 27 Dec 2023 | ₹1.44 M | Open |
How Many Employees Work at Biosphere Clinical Research?
Unlock and access historical data on people associated with Biosphere Clinical Research, such as employment history, contributions to the Employees' Provident Fund Organization (EPFO), and related information.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Biosphere Clinical Research, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Biosphere Clinical Research's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
